UCH-L1-mediated down-regulation of estrogen receptor α contributes to insensitivity to endocrine therapy for breast cancer

32Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Purpose: To determine the role of UCH-L1 in regulating ERα expression, and to evaluate whether therapeutic targeting of UCH-L1 can enhance the efficacy of anti-estrogen therapy against breast cancer with loss or reduction of ERα. Methods: Expressions of UCH-L1 and ERα were examined in breast cancer cells and patient specimens. The associations between UCH-L1 and ERα, therapeutic response and prognosis in breast cancer patients were analyzed using multiple databases. The molecular pathways by which UCH-L1 regulates ERα were analyzed using immunoblotting, qRT-PCR, immunoprecipitation, ubiquitination, luciferase and ChIP assays. The effects of UCH-L1 inhibition on the efficacy of tamoxifen in ERα (-) breast cancer cells were tested both in vivo and in vitro. Results: UCH-L1 expression was conversely correlated with ERα status in breast cancer, and the negative regulatory effect of UCH-L1 on ERα was mediated by the deubiquitinase-mediated stability of EGFR, which suppresses ERα transcription. High expression of UCH-L1 was associated with poor therapeutic response and prognosis in patients with breast cancer. Up-regulation of ERα caused by UCH-L1 inhibition could significantly enhance the efficacy of tamoxifen and fulvestrant in ERα (-) breast cancer both in vivo and in vitro. Conclusions: Our results reveal an important role of UCH-L1 in modulating ERα status and demonstrate the involvement of UCH-L1-EGFR signaling pathway, suggesting that UCH-L1 may serve as a novel adjuvant target for treatment of hormone therapy-insensitive breast cancers. Targeting UCH-L1 to sensitize ER negative breast cancer to anti-estrogen therapy might represent a new therapeutic strategy that warrants further exploration.

References Powered by Scopus

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

66839Citations
N/AReaders
Get full text

Cancer cell cycles

5111Citations
N/AReaders
Get full text

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

3733Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Progress of breast cancer basic research in china

69Citations
N/AReaders
Get full text

Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity

58Citations
N/AReaders
Get full text

UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology

43Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chen, X. S., Wang, K. S., Guo, W., Li, L. Y., Yu, P., Sun, X. Y., … Cheng, Y. (2020). UCH-L1-mediated down-regulation of estrogen receptor α contributes to insensitivity to endocrine therapy for breast cancer. Theranostics, 10(4), 1833–1848. https://doi.org/10.7150/thno.39814

Readers over time

‘20‘21‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

53%

Researcher 6

40%

Professor / Associate Prof. 1

7%

Readers' Discipline

Tooltip

Chemistry 4

40%

Pharmacology, Toxicology and Pharmaceut... 2

20%

Medicine and Dentistry 2

20%

Biochemistry, Genetics and Molecular Bi... 2

20%

Save time finding and organizing research with Mendeley

Sign up for free
0